You are here
FDA's Arthritis Advisory Committee Recommends Approval for Dupuytren's Contracture Drug
"We are very pleased with the Advisory Committee's unanimous recommendation, which supports our view that Xiaflex has a favorable benefit to risk profile in the treatment of Dupuytren's contracture," said Armando Anido, Chief Executive Officer and President of Auxilium. "Xiaflex has the potential to provide an important new non-surgical treatment option for patients with Dupuytren's contracture, a debilitating hand condition severely affecting patients' quality of life."
The Advisory Committee's recommendation, although not binding, will be considered by the FDA in its review of the Biologics License Application that Auxilium has submitted for Xiaflex. The original target Prescription Drug User Fee (PDUFA) action date for the FDA's decision as to whether to grant marketing approval for Xiaflex was August 28, 2009. The FDA has not updated the target PDUFA action date.
Source: Food and Drug Administration